Ratings SomnoMed Limited

Equities

SOM

AU000000SOM1

Market Closed - Australian S.E. Other stock markets 01:55:35 2024-05-10 am EDT			5-day change	1st Jan Change
0.2 ^AUD	-9.09%		-4.76%	-60.00%

May. 05	SomnoMed Completes AU$16.8 Million Retail Entitlement Offer	MT
Apr. 10	Somnomed Raises AU$5.8 Million in Institutional Entitlement Offer; AU$16.8 Million Retail Component to Launch April 16	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company shows low valuation levels, with an enterprise value at 0.34 times its sales.
The company appears to be poorly valued given its net asset value.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SOMNOMED LIMITED	-60.00%	19.78M	-
ABBOTT LABORATORIES	-4.84%	182B	C+
MEDTRONIC PLC	+0.56%	110B	C
BECTON, DICKINSON AND COMPANY	-3.35%	67.92B	A
DEXCOM, INC.	+2.39%	50.96B	B-
CENCORA, INC.	+9.36%	44.7B	B-
HOYA CORPORATION	+2.70%	40.66B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+24.51%	27.6B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.63B	A-
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.98B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes